Cyanovirin-N

Drug Profile

Cyanovirin-N

Alternative Names: CV-N

Latest Information Update: 08 Aug 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Institute (USA)
  • Developer Biosyn; National Cancer Institute (USA)
  • Class Antivirals; Recombinant proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 31 Dec 2006 Discontinued - Preclinical for HIV infections treatment in USA (Topical)
  • 07 Feb 2006 The Contraceptive Research and Development Organisation (CONRAD) has acquired a non-exclusive licence to research and develop Biosyn's microbicide pipeline ,
  • 21 Jun 2005 Data presented at the 18th International Conference on Antiviral Research (ICAR-2005)have been added to the Viral Infections pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top